{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:48:13Z","timestamp":1772120893586,"version":"3.50.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jaad.2019.05.077","type":"journal-article","created":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T17:49:29Z","timestamp":1559411369000},"page":"440-459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review"],"prefix":"10.1016","volume":"82","author":[{"given":"Franchesca D.","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina N.","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley N.","family":"Elsensohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sama K.","family":"Carley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larisa M.","family":"Lehmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth G.","family":"Linden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Shiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jaad.2019.05.077_bib1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jaad.2019.05.077_bib2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"18","key":"10.1016\/j.jaad.2019.05.077_bib3","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"issue":"5256","key":"10.1016\/j.jaad.2019.05.077_bib4","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.jaad.2019.05.077_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jaad.2019.05.077_bib6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2019.05.077_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jaad.2019.05.077_bib8","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jaad.2019.05.077_bib9","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jaad.2019.05.077_bib10","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"issue":"26","key":"10.1016\/j.jaad.2019.05.077_bib11","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jaad.2019.05.077_bib12","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1016\/S1470-2045(17)30607-1","article-title":"De-novo and acquired resistance to immune checkpoint targeting","volume":"18","author":"Syn","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7463","key":"10.1016\/j.jaad.2019.05.077_bib13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jaad.2019.05.077_bib14","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/bjd.14905","article-title":"Programmed cell death protein-1 inhibitors for immunotherapy of advanced nonmelanoma skin cancer: showing early promise","volume":"175","author":"Soura","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.05.077_bib15","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2019.05.077_bib16","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2011"},{"key":"10.1016\/j.jaad.2019.05.077_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2019.05.077_bib18","author":"Howick"},{"issue":"4","key":"10.1016\/j.jaad.2019.05.077_bib19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 Blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1016\/j.jaad.2019.05.077_bib20","article-title":"Primary analysis of phase 2 results for cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC)","volume":"36","author":"Rischin","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5_suppl","key":"10.1016\/j.jaad.2019.05.077_bib21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1200\/JCO.2018.36.5_suppl.195","article-title":"Cemiplimab (REGN2810): a fully human anti-PD-1 monoclonal antibody for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)\u2014initial safety and efficacy from expansion cohorts (ECs) of phase I study","volume":"36","author":"Papadopoulos","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.jaad.2019.05.077_bib22","article-title":"Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): final efficacy and safety data","volume":"36","author":"Owonikoko","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2019.05.077_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-016-0176-3","article-title":"Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810","volume":"4","author":"Falchook","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.jaad.2019.05.077_bib24","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1111\/bjd.14642","article-title":"Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases","volume":"175","author":"Borradori","year":"2016","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.05.077_bib25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/jamadermatol.2016.3884","article-title":"Follow-up on programmed cell death 1 inhibitor for cutaneous squamous cell carcinoma","volume":"153","author":"Tran","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.05.077_bib26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1684\/ejd.2017.3209","article-title":"Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases","volume":"28","author":"Blum","year":"2018","journal-title":"Eur J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.05.077_bib27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/jcm7010010","article-title":"Clinical remission of cutaneous squamous cell carcinoma of the auricle with cetuximab and nivolumab","volume":"7","author":"Chen","year":"2018","journal-title":"J Clin Med"},{"issue":"15_suppl","key":"10.1016\/j.jaad.2019.05.077_bib28","doi-asserted-by":"crossref","first-page":"9534","DOI":"10.1200\/JCO.2018.36.15_suppl.9534","article-title":"Pembrolizumab as first line therapy in patients with unresectable squamous cell carcinoma of the skin: interim results of the phase 2 CARSKIN trial","volume":"36","author":"Maubec","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.jaad.2019.05.077_bib29","article-title":"PD-1 inhibition in cutaneous squamous cell carcinoma (cSCC). 2018 ASCO Annual Meeting Abstracts","volume":"36","author":"Hermel","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2019.05.077_bib30","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/jamadermatol.2015.2705","article-title":"A case report of unresectable cutaneous squamous cell carcinoma responsive to pembrolizumab, a programmed cell death protein 1 inhibitor","volume":"152","author":"Chang","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.05.077_bib31","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/bjd.14664","article-title":"Anti-programmed cell death-1 therapy in nonmelanoma skin cancer","volume":"176","author":"Winkler","year":"2017","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.05.077_bib32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clsc.2016.11.001","article-title":"Unresectable cutaneous squamous cell carcinoma of the forehead with MLH1 mutation showing dramatic response to programmed cell death protein 1 inhibitor therapy","volume":"1","author":"Assam","year":"2018","journal-title":"Clin Skin Cancer"},{"issue":"9","key":"10.1016\/j.jaad.2019.05.077_bib33","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMc1509268","article-title":"Tumor regression and allograft rejection after administration of anti-PD-1","volume":"374","author":"Lipson","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaad.2019.05.077_bib34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1200\/JOP.2017.027326","article-title":"Complete tumor response to pembrolizumab and allograft preservation in renal allograft recipient on immunosuppressive therapy","volume":"14","author":"Sadaat","year":"2018","journal-title":"J Oncol Pract"},{"issue":"4","key":"10.1016\/j.jaad.2019.05.077_bib35","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jamadermatol.2016.5118","article-title":"Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab","volume":"153","author":"Stevenson","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"June","key":"10.1016\/j.jaad.2019.05.077_bib36","first-page":"1","article-title":"Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy","volume":"1","author":"Ikeda","year":"2016","journal-title":"NPJ Genom Med"},{"issue":"8","key":"10.1016\/j.jaad.2019.05.077_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms18081663","article-title":"Appearance of new cutaneous superficial basal cell carcinomas during successful nivolumab treatment of refractory metastatic disease: implications for immunotherapy in early versus late disease","volume":"18","author":"Cohen","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.jaad.2019.05.077_bib38","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jaad.2018.08.017","article-title":"Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study","volume":"80","author":"Chang","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.05.077_bib39","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jdcr.2018.01.015","article-title":"A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery","volume":"4","author":"Cannon","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"6","key":"10.1016\/j.jaad.2019.05.077_bib40","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1159\/000487084","article-title":"Anti-PD-1 Therapy leads to near-complete remission in a patient with metastatic basal cell carcinoma","volume":"41","author":"Fischer","year":"2018","journal-title":"Oncol Res Treat"},{"issue":"3","key":"10.1016\/j.jaad.2019.05.077_bib41","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/bjd.16607","article-title":"Effective anti-programmed death-1 therapy in a SUFU-mutated patient with Gorlin-Goltz syndrome","volume":"179","author":"Moreira","year":"2018","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2019.05.077_bib42","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.jaad.2019.05.077_bib43","doi-asserted-by":"crossref","first-page":"e180077","DOI":"10.1001\/jamaoncol.2018.0077","article-title":"Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma","volume":"4","author":"D'Angelo","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2019.05.077_bib44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40425-017-0310-x","article-title":"Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after \u2265 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial","volume":"6","author":"Kaufman","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.jaad.2019.05.077_bib45","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/RLU.0000000000002051","article-title":"F-FDG PET\/CT for monitoring response of Merkel cell carcinoma to the novel programmed cell death ligand 1 inhibitor avelumab","volume":"43","author":"Eshghi","year":"2018","journal-title":"Clin Nucl Med"},{"issue":"February","key":"10.1016\/j.jaad.2019.05.077_bib46","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1210\/jc.2017-01905","article-title":"Anti\u2013PD-L1 treatment induced central diabetes insipidus","volume":"103","author":"Zhao","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2019.05.077_bib47","doi-asserted-by":"crossref","first-page":"CT074","DOI":"10.1158\/1538-7445.AM2017-CT074","article-title":"Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1\/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): efficacy and safety in Merkel cell carcinoma (MCC)","volume":"77","author":"Topalian","year":"2017","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.jaad.2019.05.077_bib48","first-page":"1","article-title":"Response to anti-PD-1 therapy in metastatic Merkel cell carcinoma metastatic to the heart and pancreas","volume":"7","author":"Mantripragada","year":"2015","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.jaad.2019.05.077_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-016-0186-1","article-title":"Metastatic Merkel cell carcinoma response to nivolumab","volume":"4","author":"Walocko","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"26","key":"10.1016\/j.jaad.2019.05.077_bib50","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2019.05.077_bib51","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40425-018-0352-8","article-title":"In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series","volume":"6","author":"Xu","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"19","key":"10.1016\/j.jaad.2019.05.077_bib52","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2019.05.077_bib53","author":"Roche"},{"issue":"1","key":"10.1016\/j.jaad.2019.05.077_bib54","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bjd.14632","article-title":"PD-1 blockade: a therapeutic option for treatment of metastatic Merkel cell carcinoma","volume":"176","author":"Winkler","year":"2017","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.05.077_bib55","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1097\/IOP.0000000000001078","article-title":"Biopsy-proven metastatic Merkel cell carcinoma to the orbit","volume":"34","author":"Cugley","year":"2018","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"4","key":"10.1016\/j.jaad.2019.05.077_bib56","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/bjd.16780","article-title":"Pembrolizumab-associated mucous membrane pemphigoid in a Merkel cell carcinoma patient","volume":"179","author":"Haug","year":"2018","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.05.077_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-017-0311-9","article-title":"Cytokine release syndrome after radiation therapy: case report and review of the literature","volume":"6","author":"Barker","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"23","key":"10.1016\/j.jaad.2019.05.077_bib58","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib atudy","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2019.05.077_bib59","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/jamaoncol.2017.1617","article-title":"Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas a phase 2 clinical trial","volume":"4","author":"Toulmonde","year":"2018","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.jaad.2019.05.077_bib60","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.jaad.2019.05.077_bib61","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdw243","article-title":"Successful treatment of refractory leiomyosarcoma with the PD-1 inhibitor nivolumab","volume":"27","author":"Heine","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2019.05.077_bib62","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2326-6066.CIR-18-0121","article-title":"Successful treatment of HIV-associated Kaposi sarcoma with immune checkpoint blockade","volume":"14","author":"Galanina","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.jaad.2019.05.077_bib63","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/annonc\/mdy006","article-title":"PD-1 blockade with nivolumab in endemic Kaposi sarcoma","volume":"29","author":"Delyon","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.jaad.2019.05.077_bib64","doi-asserted-by":"crossref","first-page":"797","DOI":"10.6004\/jnccn.2018.7018","article-title":"Response to checkpoint inhibitor therapy in advanced classic Kaposi sarcoma: a case report and immunogenomic study","volume":"16","author":"Saller","year":"2018","journal-title":"J Natl Compr Cancer Netw"},{"issue":"suppl_5","key":"10.1016\/j.jaad.2019.05.077_bib65","first-page":"v521","article-title":"1506P\u2014PD-L1 inhibition\u2014a new therapeutic opportunity in cutaneous angiosarcoma?","volume":"28","author":"Hamacher","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2019.05.077_bib66","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40425-017-0263-0","article-title":"Angiosarcoma treated successfully with anti-PD-1 therapy\u2014a case report","volume":"5","author":"Sindhu","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.jaad.2019.05.077_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26837","article-title":"Dramatic response to nivolumab in xeroderma pigmentosum skin tumor","volume":"65","author":"Chambon","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.jaad.2019.05.077_bib68","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40425-018-0357-3","article-title":"Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma","volume":"6","author":"Domingo-Musibay","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"October","key":"10.1016\/j.jaad.2019.05.077_bib69","article-title":"Complete response to pembrolizumab in a patient with malignant peripheral nerve sheath tumor: the first case reported","author":"Payandeh","year":"2017","journal-title":"J Appl Pharm Sci"},{"issue":"6","key":"10.1016\/j.jaad.2019.05.077_bib70","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jdcr.2018.01.016","article-title":"Cutaneous CD56(+) T-cell lymphoma developing during pembrolizumab treatment for metastatic melanoma","volume":"4","author":"Zheng","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"10","key":"10.1016\/j.jaad.2019.05.077_bib72","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1517\/14656566.2015.1052743","article-title":"Pharmacologic treatment options for advanced epithelial skin cancer","volume":"16","author":"Soura","year":"2015","journal-title":"Expert Opin Pharmacother"},{"issue":"5_suppl","key":"10.1016\/j.jaad.2019.05.077_bib73","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1200\/JCO.2018.36.5_suppl.188","article-title":"Intralesional anti-PD1 treatment in patients with metastatic melanoma: the pilot study","volume":"36","author":"Samoylenko","year":"2018","journal-title":"J Clin Oncol"},{"issue":"14 Supplement","key":"10.1016\/j.jaad.2019.05.077_bib74","doi-asserted-by":"crossref","first-page":"CT134","DOI":"10.1158\/1538-7445.AM2016-CT134","article-title":"Abstract CT134: intratumoral electroporation of plasmid IL-12 can prime response to anti-PD1\/PD-L1 blockade in patients with stage III\/IV-M1a melanoma","volume":"76","author":"Algazi","year":"2016","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.jaad.2019.05.077_bib75","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2019.05.077_bib76","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/1574892811666160226150506","article-title":"Predictive efficacy biomarkers of programmed cell death 1\/programmed cell death 1 ligand blockade therapy","volume":"11","author":"Fang","year":"2016","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"4","key":"10.1016\/j.jaad.2019.05.077_bib77","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"issue":"September","key":"10.1016\/j.jaad.2019.05.077_bib78","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.2217\/fon-2017-0305","article-title":"Avelumab and other recent advances in Merkel cell carcinoma","volume":"13","author":"Bommareddy","year":"2017","journal-title":"Future Oncol"},{"issue":"3","key":"10.1016\/j.jaad.2019.05.077_bib79","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12032-018-1080-0","article-title":"The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma","volume":"35","author":"Uryvaev","year":"2018","journal-title":"Med Oncol"},{"issue":"3","key":"10.1016\/j.jaad.2019.05.077_bib80","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1016\/j.cllc.2018.01.002","article-title":"Safety and efficacy of PD-1\/PD-L1 inhibitors in treatment-naive and chemotherapy-refractory patients with non-small-cell lung cancer: a systematic review and meta-analysis","volume":"19","author":"Khunger","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jaad.2019.05.077_bib81","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ctrv.2017.12.004","article-title":"Cancer immunotherapy in a neglected population: the current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients","volume":"63","author":"Chae","year":"2018","journal-title":"Cancer Treat Rev"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219308813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219308813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:53:40Z","timestamp":1759272820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219308813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0190962219308813"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.05.077","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735907559.793567570","asserted-by":"object"}]},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.05.077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}